Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.165 USD | -2.91% | -7.81% | -26.92% |
May. 07 | Investor Sentiment Muted After Rate Cut Optimism, Stifling US Equity Futures Pre-Bell | MT |
May. 07 | Top Premarket Gainers | MT |
Financials (USD)
Sales 2024 * | 323M | Sales 2025 * | 417M | Capitalization | 422M |
---|---|---|---|---|---|
Net income 2024 * | -10M | Net income 2025 * | 46M | EV / Sales 2024 * | 0.62 x |
Net cash position 2024 * | 223M | Net cash position 2025 * | 342M | EV / Sales 2025 * | 0.19 x |
P/E ratio 2024 * |
-37.9
x | P/E ratio 2025 * |
12.5
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
Latest transcript on Esperion Therapeutics, Inc.
1 day | -1.57% | ||
1 week | -8.02% | ||
Current month | +10.66% | ||
1 month | +12.66% | ||
3 months | -16.48% | ||
6 months | +100.00% | ||
Current year | -27.09% |
Managers | Title | Age | Since |
---|---|---|---|
Sheldon Koenig
CEO | Chief Executive Officer | 58 | 20-12-14 |
Director of Finance/CFO | 38 | 19-12-31 | |
JoAnne Foody
CTO | Chief Tech/Sci/R&D Officer | 59 | 21-06-27 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 52 | 22-04-27 | |
J. Carroll
CHM | Chairman | 74 | 22-05-31 |
Alan Fuhrman
BRD | Director/Board Member | 67 | 20-03-15 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 234 M€ | +2.85% | - | |
0.00% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-14 | 2.18 | -2.24% | 2 413 314 |
24-05-13 | 2.23 | +1.83% | 4,425,062 |
24-05-10 | 2.19 | +4.78% | 9,425,974 |
24-05-09 | 2.09 | +2.45% | 7,469,605 |
24-05-08 | 2.04 | -13.92% | 13,971,539 |
Delayed Quote Nasdaq, May 14, 2024 at 11:46 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.09% | 422M | |
+29.68% | 682B | |
+30.35% | 586B | |
-3.79% | 364B | |
+17.53% | 327B | |
+3.51% | 285B | |
+15.53% | 240B | |
+10.16% | 209B | |
-8.14% | 203B | |
+7.21% | 165B |
- Stock Market
- Equities
- ESPR Stock